NEW YORK, July 02, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) stockholders concerning the proposed acquisition of the company by Akebia Therapeutics, Inc.
Pursuant to the proposed transaction, which is valued at approximately $1.3 billion, Keryx stockholders will receive 0.37433 in stocks per share of their Keryx common stock. The investigation concerns whether the Keryx Board obtained the best price possible for Keryx stockholders.
If you own Keryx shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Keryx Biopharmaceuticals, Inc. please go to https://bespc.com/keryx-2/. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 308-1869
investigations@bespc.com
www.bespc.com